Freenome

Freenome is a company based in South San Francisco, United States. Since 2014, it has pursued a vision to detect cancer in its earliest, most treatable stages. Freenome combines science and artificial intelligence with the ease of a standard blood draw, and its intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages. Its Personalized Cancer Detection approach combines risk-based screening with indication-specific blood-based tests through a simple blood draw, and the SimpleScreen™ portfolio starts with SimpleScreen Lung and SimpleScreen CRC, with additional indications in development. Freenome's clinical research program drives discovery, development, and validation of its early cancer detection tests, including the PREEMPT CRC Study, the PROACT LUNG Study, and the Vallania Study.

Since 2014, Freenome has had a clear vision—to detect cancer in its earliest, most treatable stages. Freenome is setting a new pace for early cancer detection by combining the latest in science and artificial intelligence, with the ease of a standard blood draw. Its intelligent screening platform uses multiomics technology to detect cancer in its earliest, most treatable stages. Freenome's research programs drive discovery, development, and validation of its early cancer detection tests. Its Personalized Cancer Detection approach combines risk-based screening with indication-specific blood-based tests, all through a simple blood draw, and the SimpleScreen™ portfolio starts with SimpleScreen Lung and SimpleScreen CRC, with additional indications in development. Freenome's clinical research program includes the PREEMPT CRC Study, the PROACT LUNG Study, and the Vallania Study.

Cancer screening should be simple, accessible and effective; Freenome is developing blood-based screening tests designed to detect cancer at its earliest, most treatable stages — helping expand access to screening through the ease of a standard blood draw.

• SimpleScreen Lung

  A laboratory-developed test for lung cancer screening, for adults ages 50-80 with a 20 pack-year history of smoking who have not completed lung cancer screening with low-dose CT.

• SimpleScreen CRC

  An FDA-approved blood-based screening test for colorectal cancer, for adults ages 45 and older at average risk for colorectal cancer who have not completed colonoscopy or stool-based colorectal cancer screening.

• 2021.12.07

  Reported2021.12.07

  Freenome announced $300 million Series D financing[5]Freenome 宣布完成 3 亿美元 D 轮融资prnewswire.com

  Freenome announced a $300 million Series D financing. The company said the funding would support advancement of its colorectal cancer screening test and expansion of its multiomics platform to other cancers.

Read more

1. 1Freenome | Outpacing cancer starts with early detectionfreenome.com
2. 2Our Company | Learn About Freenome's Teamfreenome.com
3. 3SimpleScreen Portfolio - Freenomefreenome.com
4. 4Clinical Expertise | Freenomefreenome.com
5. 5Freenome 宣布完成 3 亿美元 D 轮融资prnewswire.com